Jean-Frédéric Chibret

Laboratoires Théa SAS manufactures and markets eye care products. The firm offers dry eyes, allergy, herpes and eye hygiene. The company was founded by Henri Chibret in 1994 and is headquartered in Clermont-Ferrand, France.

Part of Thea Holding SAS, Thea Pharmaceuticals Ltd. is a British company that manufactures and distributes ophthalmic care products. The company is based in Newcastle-under-Lyme, UK. The company was founded in 2008. Thea Pharmaceuticals was acquired by Laboratoires Théa SAS from Vision Pharmaceuticals Ltd. on June 17, 2014.

Théa Pharma GmbH is a research laboratory that specializes in eye health. The private company was founded in 1870 and is based in Berlin, Germany. The CEOs are Jean-Frédéric Chibret and Christoph Kessler. Théa Pharma offers a comprehensive range of treatment free of preservatives that takes into account the precious of the eye. The German company provides further training through its medical library and Théa Akademie online continuous training. Théa Pharma also offers products such as the EasyGrip® multi-dose bottle, which makes handling even more user-friendly, especially for the elderly. The company's anniversary brochure describes 150 years of ophthalmology history based on those of the Chibret family who carries ophthalmology in the genes.

Thea Holding operates as a investment company. The company is headquartered in Clermont-Ferrand, France.

Part of KBC Group NV, Thea Pharma NV is a Belgian pharmaceutical company that specializes in the treatment of eye diseases such as blepharitis, dry eyes, glaucoma, and age-related macular degeneration. The company is based in Wetteren, Belgium and was founded in 2000 by Henri Roger Pierre Chibret. Thea Pharma offers a range of products including medicines, medical devices, cosmetics, and dietary supplements. The company is committed to using fewer preservatives in their products and has expertise in the harmful effects of preservatives. Thea Pharma also has a foundation that supports various projects related to eye health.

Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France.